Figure 1. OS and PFS through 5 years with NIVO+IPI vs SUN in ITT patients and by IMDC risk category4
CI, confidence interval; IPI, ipilimumab; ITT, intent-to-treat; NIVO, nivolumab; OS, overall survival; PFS, progression-free survival; SUN, sunitinib